SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novo Nordisk adds Anthropic's Claude to drug-research workflow

Novo Nordisk (NYSE: NVO) will test Anthropic’s Claude Science on selected scientific questions and deploy it in its drug-research workflow,

NVONOVOB

S. 125. Novo said it will start by testing Claude Science on selected scientific questions while also deploying…